AVXL Anavex Life Sciences Corp. - 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing.

On May 20, 2026, Anavex Life Sciences Corp. (the “Company”)
received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market
LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule
5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

The Notice has no immediate effect on the listing
of the Company’s common stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.

As indicated in the Notice, the Company has until
July 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, it may grant an exception of up to 180
calendar days from the Form 10-Q’s due date, or until November 16, 2026, for the Company to regain compliance. If Nasdaq does not
accept the Company’s compliance plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel.

The Company is working prudently to complete and file
the Form 10-Q and submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).

Item 8.01. Other Events.

On May 22, 2026, the Company issued a press release
announcing the Company’s receipt of the Notice. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated
by reference into this Item 8.01.

Cautionary Note Regarding Forward-Looking Statements

Statements in this Current Report on Form 8-K that
are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating
to the Company’s plans to complete and file the Form 10-Q and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).
These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results
may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited
to, risks related to the Company’s ability to file the Form 10-Q and the Company’s ability to regain compliance with Nasdaq
Listing Rule 5250(c)(1) and other the risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update these statements
to reflect events or circumstances after the date hereof except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated May 22, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).